Evotaz (Atazanavir Sulfate/Cobicistat) Patent Expiration, LOE Window & CMS Spending

Evotaz (Atazanavir Sulfate/Cobicistat) by Bristol Myers Squibb: FDA Orange Book core substance LOE 2029-09-03 (last listed 2032-10-06), 0 AB generics, $14.3M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBristol Myers Squibb
FDA Application & PathwayN206353 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2029-09-03
Last Listed Patent or Exclusivity Date2032-10-06
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$14.3M
2024 Medicare Part D Spend$10.2M
2024 Medicaid Spend$4.1M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.